Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024. Ms. Nassif is an ...

Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for ...

This is a news collection page for Canberra. Check this page for latest news headlines covering major stories, events from Canberra and surrounding ACT. Get breaking news faster than any other ...

STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

The many doctors I met decided to participate in our trials because they made their own assessment of simufilam, and they ...

More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Cassava Sciences, Inc., a clinical-stage biotechnology company based in Austin, Texas, focuses on developing novel treatments for neurodegenerative diseases, particularly Alzheimer’s disease, through ...

Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...